WiseHeart Med Completes Tens of Millions RMB Pre-A Financing to Advance Stem Cell Therapy for Neurological Disorders

Recently, Beijing Huixin Wiseheart Medval Biotechnology Co., Ltd. (hereinafter referred to as “Wiseheart Medval”) announced the completion of its pre-A financing round, raising tens of millions of RMB. The round was led by North Venture Capital, with follow-on investment from Jiuzhi Capital. The funds will be used to advance the development and clinical efficacy validation of Wiseheart Medval’s next-generation stem cell therapies for neurological disorders.

Wiseheart Medval, established in July 2021, is dedicated to applying its internationally leading, independently owned intellectual property rights in induced neural stem cell (iNSC) technology to drug research and the development of innovative therapies for nervous system diseases. Its first pipeline candidate is an injectable formulation of dopaminergic neural precursor cells derived from induced neural stem cells (iNSC-DAPs), designed for the treatment of Parkinson’s disease. This internationally leading Class I biologic novel drug is administered via intracranial injection to replace and supplement necrotic dopaminergic neurons, thereby restoring physiological dopamine secretion in the brain. The therapy aims to provide long-term efficacy and symptom relief with a single transplantation, while also halting disease progression. In July 2023, the world’s first neurosurgical procedure using autologous iNSC-DAP cell transplantation for the treatment of Parkinson’s disease was successfully performed at Xuanwu Hospital of Capital Medical University.

After more than two years of development, the company has established an exciting platform for the research and development and industrialization of cell-based therapies. Wiseheart Medval has always adhered to a clinical value-oriented philosophy in new drug development, dedicated to researching innovative therapies centered on patient benefit. This holds significant importance for advancing the pharmaceutical sector and improving patient health outcomes.

Mr. He Jingwei, Chairman of North Venture Capitalstated that innovative cell therapies hold significant application prospects in the treatment of neurological diseases. The first iNSC-DAP cell injection, independently developed by Wiseheart Medval, has initially been clinically validated. We eagerly anticipate its early market launch to benefit a broad population of Parkinson’s disease patients.

Mr. Han Hualong, Director of Jiuzhi CapitalIt was stated that novel stem cell therapies represent one of the most cutting-edge frontiers in current medical research. With the successive implementation of policy frameworks supporting the entire industrial chain in China, this field is poised to yield a batch of original achievements with international influence. In its strategic layout within this sector, Wiseheart Medval places significant emphasis on its distinct advantages in technological innovation and clinical translation.

Beijing Innovation Venture Capital Co., Ltd. is committed to building itself into a leading, market-oriented state-owned venture capital platform with significant industry influence across China. As a market-oriented innovation investment platform within the Beijing State-owned Assets Supervision and Administration system, North Venture Capital (NVC) will fully leverage the advantages of its mixed-ownership structure. Through innovative investment operations and fund investment management, NVC covers investments ranging from technological innovation to high-end, precision-cutting-edge industries. It incubates the industrialization of scientific and technological achievement transformation projects, guiding advantageous projects that align with Beijing’s strategic positioning and drive industrial development to establish themselves in Beijing. By leveraging its advantages in industry-finance empowerment services, NVC integrates the industrial resources of Beijing’s municipal state-owned enterprises (SOEs), promotes the adjustment of state-owned capital layout, supports the transformation and upgrading of municipal SOEs, improves their industrial ecosystem, fosters the clustered development of Beijing’s high-end, precision-cutting-edge industries and specialized, refined, distinctive, and innovative (“Little Giant”) enterprises, contributes to the construction of Beijing as a global center for scientific and technological innovation, and facilitates the optimization and adjustment of the state-owned economy’s layout.

Jiuzhi Capital, established in June 2008, is a premier investment firm in China deeply rooted in the high-tech industry. Its management team primarily hails from renowned universities such as Tsinghua University, Peking University, and Zhejiang University. The company maintains extensive and in-depth collaborations with these institutions in the commercialization of scientific and technological achievements and equity investment in sci-tech innovation. Jiuzhi Capital focuses on high-tech sectors including new energy, new materials, semiconductors, equipment manufacturing, biopharmaceuticals, and aerospace.

As a key partner of state-owned enterprises (SOEs) and financial institutions—including State Power Investment Corporation, Industrial and Commercial Bank of China, Agricultural Bank of China, China Minsheng Bank, and Bank of Hangzhou—in the field of sci-tech innovation investment, Jiuzhi Capital has jointly established a series of sci-tech innovation equity investment funds with multiple SOEs and financial institutions. These partnerships provide comprehensive support to invested high-tech enterprises, covering business strategy expansion, credit facilities, and supply chain finance.

Jiuzhi Capital has successively invested in more than 100 high-tech enterprises, including BYD (002594, formerly the fifth-largest shareholder), Hoymiles Power Electronics (688032, the third-largest shareholder), Leapmotor (HK9863, the fifth-largest shareholder), Qiyuan Core Power, and SVOLT.